7,835 results match your criteria Lymphoma Cutaneous T-Cell


Suppressed microRNA-195-5p expression in mycosis fungoides promotes tumor cell proliferation.

Exp Dermatol 2020 Jun 3. Epub 2020 Jun 3.

Department of Dermatology, Aarhus University Hospital, Aarhus, Denmark.

Background: Several cancers, including mycosis fungoides (MF), have reported dysregulation of miR-195-5p. miR-195-5p plays a role in cell cycle regulation in several malignant diseases.

Objectives: This study aimed to investigate: i) the expression level of miR-195-5p in lesional MF skin biopsies and II) the potential regulatory roles of miR-195-5p in MF. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/exd.14124DOI Listing

Lymphomatoid papulosis successfully managed with excimer laser maintenance therapy.

JAAD Case Rep 2020 Jun 18;6(6):495-497. Epub 2020 Apr 18.

Department of Dermatology, University of California, San Francisco, California.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.jdcr.2020.04.005DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7256238PMC

A rare association of bullous pemphigoid with mycosis fungoides and Sézary syndrome.

JAAD Case Rep 2020 Jun 1;6(6):486-488. Epub 2020 May 1.

Dr. Phillip Frost Department of Dermatology and Cutaneous Surgery, University of Miami Miller School of Medicine, Miami, Florida.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.jdcr.2020.04.024DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7256241PMC

Pityriasis Lichenoides Chronica in a Patient With Ankylosing Spondylitis Treated With Etanercept.

J Drugs Dermatol 2020 May;19(5):560-561

Background: Pityriasis lichenoides chronica, a papulosquamous disorder often considered a subtype of pityriasis lichenoides. It is considered a clonal T-cell disorder, which may be associated with cutaneous T-cell lymphoma that may develops in response to foreign antigens.

Case Presentation: We present a 38-year-old male patient with ankylosing spondylitis who was on treatment with etanercept. Read More

View Article

Download full-text PDF

Source

A case of cutaneous extranodal natural killer/T-cell lymphoma clinically and histopathologically mimicking interface dermatitis.

Australas J Dermatol 2020 Jun 2. Epub 2020 Jun 2.

Department of Dermatology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Korea.

Extranodal natural killer/T-cell lymphoma (ENKTL) is a rare but aggressive cancer characterised by angiocentric and angiodestructive infiltration by NK-cells, or cytotoxic T-cell types. Histopathologically, ENKTL shows a multinodular or diffuse infiltration localised to vascular structures, resulting in angiodestruction and necrosis. We present a patient with an initially suspected diagnosis of benign interface dermatitis with a differential diagnosis of mycosis fungoides that was later found to be an aggressive extranodal natural killer/T-cell lymphoma of a nasal type and with a dismal prognosis. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/ajd.13304DOI Listing

Update on Biology of Cutaneous T-Cell Lymphoma.

Front Oncol 2020 12;10:765. Epub 2020 May 12.

Department of Dermatology, Johns Hopkins University, Baltimore, MD, United States.

Cutaneous T cell lymphomas (CTCL) comprise of a heterogeneous group of non-Hodgkin lymphomas derived from skin-homing T cells. Variation in clinical presentation and lack of definitive molecular markers make diagnosis especially challenging. The biology of CTCL remains elusive and clear links between genetic aberrations and epigenetic modifications that would result in clonal T cell expansion have not yet been identified. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3389/fonc.2020.00765DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7235328PMC

Mogamulizumab-induced Mucocutaneous Lichenoid Reaction: A Case Report and Short Review.

Acta Derm Venereol 2020 May 28;100(10):adv00158. Epub 2020 May 28.

College of Physicians and Surgeons, Columbia University Vagelos, New York, USA.

is missing (Short communication). Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.2340/00015555-3527DOI Listing

Genome-wide transcriptome analysis of the STAT6-regulated genes in advanced-stage cutaneous T-cell lymphoma.

Blood 2020 May 21. Epub 2020 May 21.

Unversity of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania, United States.

The signal transducer and activator of transcription 6 (STAT-6) is a critical up-stream mediator of IL-13 and IL-4 signaling and is constitutively activated in malignant lymphocytes from Sezary syndrome (SS) and mycosis fungoides (MF), the most common subtypes of cutaneous T-cell lymphomas. By combining genome-wide expression profiling with pharmacological STAT-6 inhibition, we have identified the genes regulated by STAT-6 in MF/SS tumors. We found that STAT-6 regulates several common pathways in MF/SS malignant lymphocytes that are associated with control of cell cycle progression and genomic stability as well as production of Th2 cytokines. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1182/blood.2019004725DOI Listing

CD30 positive Leukemic Cutaneous T Cell Lymphoma.

J Am Acad Dermatol 2020 May 10. Epub 2020 May 10.

Department of Dermatology, University Hospitals Cleveland Medical Center/Case Western Reserve University School of Medicine, Cleveland, OH, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.jaad.2020.05.014DOI Listing

JAK inhibition synergistically potentiates BCL2, BET, HDAC, and proteasome inhibition in advanced CTCL.

Blood Adv 2020 May;4(10):2213-2226

Department of Dermatology, Yale School of Medicine, New Haven, CT.

Cutaneous T-cell lymphoma (CTCL) is a malignancy of skin-homing T lymphocytes that is more likely to involve the peripheral blood in advanced stages. For such patients with advanced disease, there are few available systemic treatment options, and prognosis remains poor. Exome sequencing studies of CTCL have suggested therapeutic targets, including within the JAK/STAT pathway, but JAK inhibition strategies may be limited by patient-specific mutational status. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1182/bloodadvances.2020001756DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7252559PMC

Primary Cutaneous CD30+ Lymphoproliferative Disorders: a Comprehensive Review.

Curr Hematol Malig Rep 2020 May 20. Epub 2020 May 20.

City of Hope National Medical Center, 1500 E. Duarte Road, Duarte, CA, 91010, USA.

Purpose Of Review: Primary cutaneous CD30+ T-cell lymphoproliferative disorders (CD30+ LPDs) are the second most common cutaneous lymphomas after mycosis fungoides and Sezary syndrome. They include primary cutaneous anaplastic large cell lymphoma (pcALCL), lymphomatoid papulosis (LyP), and borderline lesions. The purpose of this literature review is to consolidate the available evidence on the primary cutaneous CD30+ LPD in order to define the tools for correct diagnosis and appropriate treatment. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s11899-020-00583-4DOI Listing

Pityriasis Lichenoides-like Mycosis Fungoides in Children: A Challenging Diagnosis.

Korean J Fam Med 2020 May 21. Epub 2020 May 21.

Department of Dermatology, Hospital Raja Perempuan Zainab II, Kota Bahru, Malaysia.

Primary cutaneous lymphomas are rare diseases among the general population, and even rarer in children. Mycosis fungoides (MF) is the most commonly diagnosed form in childhood. Several atypical clinical variants of MF have been reported, and pityriasis lichenoides-like MF (PL-like MF) is a recently described subtype. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.4082/kjfm.20.0036DOI Listing

Allogeneic stem cell transplantation for peripheral T cell lymphomas: a retrospective study in 285 patients from the Société Francophone de Greffe de Moelle et de Thérapie Cellulaire (SFGM-TC).

J Hematol Oncol 2020 May 19;13(1):56. Epub 2020 May 19.

Department of Hematology, Hôpital Pitié Salpêtrière, Paris, France.

Background: Peripheral T cell lymphomas form a heterogeneous group with a usually dismal prognostic. The place of allogeneic stem cell transplantation to treat PTCL is debated.

Methods: We retrospectively analyzed the overall survival (OS), event-free survival (EFS), relapse, and transplant-related mortality (TRM) and associated variables in 285 adults with non-primary cutaneous PTCL (PCTL-NOS (39%), angioimmunoblastic T cell lymphomas (29%), anaplastic T cell lymphomas (15%), and other subtypes (17%)), who received alloSCT in 34 centers between 2006 and 2014. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1186/s13045-020-00892-4DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7236365PMC

Response to Topical Corticosteroid Monotherapy in Mycosis Fungoides.

J Am Acad Dermatol 2020 May 16. Epub 2020 May 16.

Department of Dermatology and Cutaneous Biology, Thomas Jefferson University, Philadelphia, PA. Electronic address:

Background: Topical corticosteroids alone or in combination with other therapies are widely used to treat Mycosis Fungoides (MF), but data on response rates to their use as monotherapy in MF are limited.

Objective: Evaluate the efficacy of topical corticosteroid monotherapy in MF; compare gender, age, stage distributions, and histopathological features between responders and non-responders.

Methods: A retrospective cross-sectional review of MF patients from 2013 to 2019 treated at Thomas Jefferson University was conducted. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.jaad.2020.05.043DOI Listing

Flow Cytometry-based Detection of B-cell Lymphoproliferative Disorders in Patients with Mycosis Fungoides.

Acta Derm Venereol 2020 May 18. Epub 2020 May 18.

Department of Dermatology, Tel Aviv Sourasky Medical Center, Sackler Faculty of Medicine, Tel Aviv University, 64239 Tel Aviv, Israel. E-mail:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.2340/00015555-3517DOI Listing

Recent advances in understanding and managing cutaneous T-cell lymphomas.

F1000Res 2020 5;9. Epub 2020 May 5.

Department of Dermatology, Medical University of Vienna, Währinger Gürtel 18-20, Vienna, 1090, Austria.

Cutaneous T-cell lymphomas (CTCLs) comprise a heterogeneous group of extranodal non-Hodgkin lymphomas involving primarily the skin and mycosis fungoides is its most frequent entity. Whereas most patients show an indolent course in early disease (clinical stages IA to IIA), some patients progress to advanced disease (stage IIB or higher), and the 5-year survival rate is unfavorable: only 47% (stage IIB) to 18% (stage IVB). Except for allogeneic stem cell transplantation, there is currently no cure for CTCL and thus treatment approaches are palliative, focusing on patients' health-related quality of life. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.12688/f1000research.21922.1DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7202086PMC

MicroRNAs in the Pathogenesis, Diagnosis, Prognosis and Targeted Treatment of Cutaneous T-Cell Lymphomas.

Cancers (Basel) 2020 May 13;12(5). Epub 2020 May 13.

LEO Foundation Skin Immunology Research Center, Department of Immunology and Microbiology, University of Copenhagen, DK-2200 Copenhagen, Denmark.

Cutaneous T-cell lymphoma (CTCL) represents a heterogeneous group of potentially devastating primary skin malignancies. Despite decades of intense research efforts, the pathogenesis is still not fully understood. In the early stages, both clinical and histopathological diagnosis is often difficult due to the ability of CTCL to masquerade as benign skin inflammatory dermatoses. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3390/cancers12051229DOI Listing

Folliculotropic mycosis fungoides: Clinical characteristics, treatments, and long-term outcomes of 53 patients in a tertiary hospital.

Dermatol Ther 2020 May 14:e13585. Epub 2020 May 14.

Faculty of Medicine, Department of Pathology, Ankara University, Ankara, Turkey.

Folliculotropic mycosis fungoides (FMF) is characterized by a broad clinical spectrum and worse prognosis compared to classical MF. This study aimed to evaluate the clinical characteristics, treatment modalities and long-term outcome and risk factors for progression and survival of FMF patients. We conducted a single-center retrospective study and reviewed 53 patients diagnosed with FMF between 1990 to 2019 in a referral center at Ankara University, Turkey. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/dth.13585DOI Listing

Staphylococcus aureus enterotoxins induce FOXP3 in neoplastic T cells in Sézary syndrome.

Blood Cancer J 2020 May 14;10(5):57. Epub 2020 May 14.

Department of Immunology and Microbiology; LEO Foundation Skin Immunology Research Center, University of Copenhagen, Copenhagen, Denmark.

Sézary syndrome (SS) is a heterogeneous leukemic subtype of cutaneous T-cell lymphoma (CTCL) with generalized erythroderma, lymphadenopathy, and a poor prognosis. Advanced disease is invariably associated with severe immune dysregulation and the majority of patients die from infectious complications caused by microorganisms such as, Staphylococcus aureus, rather than from the lymphoma per se. Here, we examined if staphylococcal enterotoxins (SE) may shape the phenotype of malignant SS cells, including expression of the regulatory T-cell-associated marker FOXP3. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1038/s41408-020-0324-3DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7225173PMC

The Novel Role of Antibiotic Treatment in the Management of Cutaneous T-Cell Lymphoma (CTCL) Patients.

J Cutan Med Surg 2020 May 12:1203475420926981. Epub 2020 May 12.

507266 Division of Dermatology, McGill University, Montreal, QC, Canada.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1177/1203475420926981DOI Listing

NCCN Guidelines Insights: Primary Cutaneous Lymphomas, Version 2.2020.

J Natl Compr Canc Netw 2020 May;18(5):522-536

14Stanford Cancer Institute.

Mycosis fungoides (MF) is the most common subtype of cutaneous T-cell lymphoma (CTCL), and Sézary syndrome (SS) is a rare erythrodermic and leukemic subtype of CTCL characterized by significant blood involvement. Although early-stage disease can be effectively treated predominantly with skin-directed therapies, systemic therapy is often necessary for the treatment of advanced-stage disease. Systemic therapy options have evolved in recent years with the approval of novel agents such as romidepsin, brentuximab vedotin, and mogamulizumab. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.6004/jnccn.2020.0022DOI Listing
May 2020
4.178 Impact Factor

New Insights Into the Complex Mutational Landscape of Sézary Syndrome.

Front Oncol 2020 21;10:514. Epub 2020 Apr 21.

Department of Malignant Hematology, H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL, United States.

Sézary syndrome (SS) is a genetically and clinically distinct entity among cutaneous T-cell lymphomas (CTCL). SS is characterized by more aggressive disease compared to the most common indolent type of CTCL, mycosis fungoides. However, there are limited available genomic data regarding SS. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3389/fonc.2020.00514DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7186303PMC

Monotherapy and combination therapy with acitretin for mycosis fungoides: results of a retrospective, multicenter study.

J Eur Acad Dermatol Venereol 2020 May 4. Epub 2020 May 4.

Department of Dermatology-Venereology, Faculty of Medicine, University of Crete, Heraklion/Crete, Greece.

Background: Retinoids have long been used in the treatment of cutaneous T-cell lymphomas. However, data on acitretin use for mycosis fungoides (MF) are very limited.

Objectives: To evaluate treatment outcomes of acitretin in patients with MF attending three academic referral centers in different regions of Greece. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/jdv.16567DOI Listing

alpha-toxin inhibits CD8 T cell-mediated killing of cancer cells in cutaneous T-cell lymphoma.

Oncoimmunology 2020 17;9(1):1751561. Epub 2020 Apr 17.

LEO Foundation Skin Immunology Research Center, Department of Immunology and Microbiology, University of Copenhagen, Copenhagen, Denmark.

and its toxins have been linked to disease progression and mortality in advanced stages of cutaneous T-cell lymphoma (CTCL). CD8 T cells play a crucial role in anti-cancer responses and high CD8 T cell numbers in tumor lesions are associated with a favorable prognosis in CTCL. Here, we show that CD8 T cells from both healthy donors and Sézary syndrome patients are highly susceptible to cell death induced by Staphylococcal alpha-toxin, whereas malignant T cells are not. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1080/2162402X.2020.1751561DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7185203PMC

Successful treatment of mogamulizumab-resistant mycosis fungoides with mogamulizumab plus etoposide combined therapy: Investigation of the immunomodulatory effects of etoposide on the tumor microenvironment.

Dermatol Ther 2020 May 2:e13487. Epub 2020 May 2.

Department of Dermatology, Tohoku University Graduate School of Medicine, Sendai, Japan.

Mogamulizumab shows cytotoxicity against CCR4+ lymphoma cells by antibody-dependent cell-mediated cytotoxicity (ADCC) in advanced cutaneous T-cell lymphoma (CTCL) patients. Although mogamulizumab is used as one of the anchor drugs for the treatment of advanced CTCL, its efficacy is unsatisfactory, especially in mycosis fungoides (MF). Therefore, additional drugs to enhance the antitumor effects of mogamulizumab are needed to further optimize its use for the treatment of MF. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/dth.13487DOI Listing

Skin microbiome in cutaneous T cell lymphoma by 16S and whole genome shotgun sequencing.

J Invest Dermatol 2020 Apr 27. Epub 2020 Apr 27.

Department of Dermatology and Allergology, University of Helsinki, and Helsinki University Hospital, Helsinki, Finland.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.jid.2020.03.951DOI Listing

Synthesis and Biological Evaluation of HDAC Inhibitors With a Novel Zinc Binding Group.

Front Chem 2020 15;8:256. Epub 2020 Apr 15.

College of Pharmacy, Hebei Medical University, Shijiazhuang, China.

Vorinostat (SAHA) with great therapeutic potential has been approved by the FDA for the treatment of cutaneous T-cell lymphoma as the first HDACs inhibitor, but the drawbacks associated with hydroxamic acid group (poor stability, easy metabolism, weak binding ability to class IIa isozymes, and poor selectivity) have been exposed during the continuous clinical application. Based on the pharmacophore of HDAC inhibitors, two series of compounds with novel zinc binding group (ZBG) were designed and synthesized, and the antitumor bioactivities were evaluated in four human cancer cell lines (A549, Hela, HepG2, and MCF-7). Among the synthesized compounds, compounds , , , , and exhibited promising inhibitory activities against the selected tumor cell lines, especially compounds and on Hela's cytostatic activity (: IC = 11. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3389/fchem.2020.00256DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7174758PMC

Methylation patterns of cutaneous T-cell lymphomas.

Exp Dermatol 2020 Apr 30. Epub 2020 Apr 30.

Institute of Human Genetics, Polish Academy of Sciences, Poznan, Poland.

In cutaneous T-cell lymphoma (CTCL), global hypomethylation of the genome and hypermethylation of tumor suppressor genes were detected. Studies show that methylation dysregulation is often a starting point for processes that might lead to malignant transformation. In this review, all data regarding copy-number variations (CNVs) and mutations in main methylation players DNA methyltransferases/TET in CTCL were summarized. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/exd.14108DOI Listing

Mycosis Fungoides of the True Vocal Folds: A Case Report.

Ann Otol Rhinol Laryngol 2020 Apr 27:3489420916213. Epub 2020 Apr 27.

Department of Surgery, Division of Otolaryngology-Head & Neck Surgery, UC San Diego, San Diego, CA, USA.

Objectives: To report a case of laryngeal involvement of mycosis fungoides and its symptomatic treatment with laser-assisted surgical ablation.

Methods: Case report and literature review.

Results: A 76-year-old woman with longstanding MF previously treated with Brentuximab Vedotin who developed persistent cough and dysphonia. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1177/0003489420916213DOI Listing

Clinical and Histopathological Characteristics of Cutaneous Lymphoid Hyperplasia: A Comparative Study According to Causative Factors.

J Clin Med 2020 Apr 23;9(4). Epub 2020 Apr 23.

Department of Dermatology, Asan Medical Center, University of Ulsan College of Medicine, Seoul 05505, Korea.

Cutaneous lymphoid hyperplasia (CLH) is a heterogeneous type of reactive lymphocytic infiltration resembling cutaneous lymphoma clinically and histopathologically. Few studies describe the relationship between the causative agents and histopathological and immunohistochemical characteristics of CLH. We investigated the clinical and histopathological characteristics of 50 patients with cutaneous CLH and analyzed them according to causative factors and predominant cell types (B or T cells). Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3390/jcm9041217DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7230858PMC

MicroRNA-93 Targets p21 and Promotes Proliferation in Mycosis Fungoides T Cells.

Dermatology 2020 Apr 24:1-6. Epub 2020 Apr 24.

Department of Dermatology, Aarhus University Hospital, Skejby, Aarhus, Denmark.

Background: Mycosis fungoides (MF), the most common form of cutaneous T-cell lymphoma (CTCL), is a lymphoproliferative disorder characterized by proliferation of malignant T cells in a chronic inflammatory environment in the skin. The nature of MF is still not fully understood, but aberrant microRNA (miR) expression and function seem to play an important role in the pathogenesis and disease progression and have been proposed as a putative disease marker. Recent studies have reported aberrant expression of miR-93 in situin MF lesions and linked dysregulated miR-93 expression to advanced stages of MF. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1159/000505743DOI Listing

The importance of differentiating between Mycosis Fungoides with CD30 positive large cell transformation and Mycosis Fungoides with co-existent primary cutaneous Anaplastic Large Cell Lymphoma.

J Am Acad Dermatol 2020 Apr 22. Epub 2020 Apr 22.

Department of Clinical Haematology, Peter MacCallum Cancer Centre and Royal Melbourne Hospital, Melbourne, Australia; Faculty of Medicine, Nursing, and Health Sciences, Monash University, Clayton, Australia. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.jaad.2020.04.073DOI Listing

Primary cutaneous peripheral T-cell lymphoma, not otherwise specified, associated with lymphomatoid papulosis after a 9-year follow up: A case report.

J Dermatol 2020 Jun 22;47(6):641-645. Epub 2020 Apr 22.

Departments of, Department of, Dermatology, Wakayama Medical University, Wakayama, Japan.

Lymphomatoid papulosis (LyP) is a self-limiting cutaneous T-cell lymphoproliferative disorder that may progress into malignant lymphoma. Most of the previously reported associated lymphomas are primary cutaneous anaplastic large-cell lymphoma and mycosis fungoides with a low mortality rate. We report a case of primary cutaneous peripheral T-cell lymphoma, not otherwise specified (pcPTCL-NOS), associated with LyP after long-term follow up. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/1346-8138.15351DOI Listing

Mogamulizumab in the treatment of advanced mycosis fungoides and Sézary syndrome: safety and efficacy.

Expert Rev Anticancer Ther 2020 Apr 28:1-6. Epub 2020 Apr 28.

Professor of Dermatology and Director of Cutaneous Lymphoma Program, Department of Dermatology, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA, USA.

: Advanced mycosis fungoides (MF) and Sézary syndrome (SS) are forms of cutaneous T-cell lymphoma characterized by a poor prognosis. Treatments are associated with high rates of relapse, and thus there exists an unmet medical need for new, improved therapies. Mogamulizumab is a novel defucosylated monoclonal antibody targeting C-C chemokine receptor 4 that eradicates malignant cells via antibody-dependent cellular cytotoxicity (ADCC). Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1080/14737140.2020.1760096DOI Listing

Consensus on the Clinical Approach to Moderate-to-Severe Atopic Dermatitis in Spain: A Delphi Survey.

Dermatol Res Pract 2020 7;2020:1524293. Epub 2020 Apr 7.

Section of Allergy, Hospital Clinic i Provincial de Barcelona, IDIBAPS, Universitat de Barcelona, Barcelona, Spain.

Background: The purpose of this study was to gather information on the current assessment and management of patients with moderate-to-severe AD in routine daily practice.

Methods: A cross-sectional two-round Delphi survey with the participation of dermatologists and allergologists throughout Spain was conducted. They completed a 46-item questionnaire, and consensus was defined when responses of ≥80% of participants coincided in the categories of a 5-point Likert scale for that item. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1155/2020/1524293DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7166259PMC

Apoptotic and anti-proliferative effect of guanosine and guanosine derivatives in HuT-78 T lymphoma cells.

Naunyn Schmiedebergs Arch Pharmacol 2020 Apr 20. Epub 2020 Apr 20.

Institute of Pharmacology, Medical School of Hannover, Carl-Neuberg-Str. 1, 30625, Hannover, Germany.

The effects of 100 μM of 3',5'-cGMP, cAMP, cCMP, and cUMP as well as of the corresponding membrane-permeant acetoxymethyl esters on anti-CD3-antibody (OKT3)-induced IL-2 production of HuT-78 cutaneous T cell lymphoma (Sézary lymphoma) cells were analyzed. Only 3',5'-cGMP significantly reduced IL-2 production. Flow cytometric analysis of apoptotic (propidium iodide/annexin V staining) and anti-proliferative (CFSE staining) effects revealed that 3',5'-cGMP concentrations > 50 μM strongly inhibited proliferation and promoted apoptosis of HuT-78 cells (cultured in the presence of αCD3 antibody). Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s00210-020-01864-8DOI Listing

Cutaneous T-cell lymphoma: aetiopathogenesis and current diagnostic and therapeutic developments.

Eur J Dermatol 2020 Apr 16. Epub 2020 Apr 16.

2nd Department of Dermatology and Venereal Diseases, Attikon General University Hospital, Medical School, National and Kapodistrian University of Athens, Athens, Greece.

Cutaneous T-cell lymphoma is a heterogeneous group of non-Hodgkin's lymphoma, characterized by an infiltration of malignant T cells in the skin. The most common subgroups include mycosis fungoides followed by the aggressive leukaemic variant, Sézary syndrome. The pathophysiology of this neoplasm is poorly understood. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1684/ejd.2020.3712DOI Listing

Combined Modality Treatment With Brentuximab Vedotin and Radiation Therapy for Primary Cutaneous Anaplastic Large Cell Lymphoma: A Case Report.

J Hematol 2019 Sep 30;8(3):132-136. Epub 2019 Sep 30.

Department of Medicine, Division of Medical Oncology and Hematology, Mayo Clinic Health System, 1221 Whipple St., Eau Claire, WI, 54703, USA.

Primary cutaneous anaplastic large cell lymphoma (pcALCL) is a rare form of non-Hodgkins lymphoma. Current frontline treatments for pcALCL include surgical resection, anthracycline-based chemotherapy, and/or radiation therapy (RT) depending on disease severity. While brentuximab vedotin (BV) has been used for refractory/relapsed cases, it recently received Food and Drug Administration (FDA) approval for use in combination with chemotherapy for peripheral T-cell lymphomas. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.14740/jh534DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7153663PMC
September 2019

Cutaneous T-cell lymphoma of the vulva.

Am J Obstet Gynecol 2020 Apr 13. Epub 2020 Apr 13.

Departments of Obstetrics and Gynaecology, National University Hospital, Singapore.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.ajog.2020.03.040DOI Listing

Cutaneous composite lymphoma of mycosis fungoides and Hodgkin lymphoma: Response to sequential therapy.

J Cutan Pathol 2020 Apr 14. Epub 2020 Apr 14.

Department of Dermatology and Venereology, Peking University First Hospital, Beijing, China.

Composite lymphoma is defined as two or more morphologically and immunophenotypically distinct lymphoma clones that occur in the same tissue site. The occurrence of cutaneous composite lymphoma (CCL) is extremely rare. Here we report a unique case of CCL consisting of Hodgkin lymphoma (HL) and mycosis fungoides (MF). Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/cup.13711DOI Listing

Synergistic cytotoxic activity of cannabinoids from against cutaneous T-cell lymphoma (CTCL) and .

Oncotarget 2020 Mar 31;11(13):1141-1156. Epub 2020 Mar 31.

Agricultural Research Organization (ARO), Volcani Center, Rishon LeZion, Israel.

produces hundreds of phytocannabinoids and terpenes. Mycosis fungoides (MF) is the most common type of cutaneous T-cell lymphoma (CTCL), characterized by patches, plaques and tumors. Sézary is a leukemic stage of CTCL presenting with erythroderma and the presence of neoplastic Sézary T-cells in peripheral blood. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.18632/oncotarget.27528DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7138167PMC

Primary Cutaneous CD30+ Anaplastic Large T Cell Lymphoma in a Patient Treated with Cyclosporine for Actinic Reticuloid.

Case Rep Dermatol Med 2020 25;2020:9435242. Epub 2020 Mar 25.

Skin Cancer Center, Department of Dermatology, Ruhr-University Bochum, Bochum, Germany.

Actinic reticuloid (AR)-a subtype of chronic actinic dermatitis-clinically and histopathologically shows lymphoma-like features. We report a male patient initially diagnosed with erythrodermic cutaneous T cell lymphoma (CTCL) who developed severe broadband photosensitivity. Clinical evaluation, histopathology, and phototesting were consistent with AR. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1155/2020/9435242DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7132347PMC

Primary Cutaneous CD4+ Small/Medium T-Cell Lymphoproliferative Disorders: A Clinical, Pathologic, and Molecular Study of 60 Cases Presenting With a Single Lesion: A Multicenter Study of the French Cutaneous Lymphoma Study Group.

Am J Surg Pathol 2020 Apr 7. Epub 2020 Apr 7.

INSERM U1053 Team 3 Oncogenesis of Cutaneous Lymphomas, Bordeaux Univsersity, Bordeaux.

Primary cutaneous CD4 small/medium T-cell lymphoproliferative disorder (PCSMLPD) is a recently recognized entity in the 2017 World Health Organization (WHO) classification. It belongs to the T-follicular helper (TFH) lymphoproliferations. The clinical, pathologic, and molecular features of this localized disease are underresearched. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1097/PAS.0000000000001470DOI Listing

Effects of Romidepsin on T-Cell Activation, Apoptosis and Function in the BCN02 HIV-1 Kick&Kill Clinical Trial.

Front Immunol 2020 20;11:418. Epub 2020 Mar 20.

IrsiCaixa AIDS Research Institute-HIVACAT, Badalona, Spain.

Romidepsin (RMD) is a well-characterized histone deacetylase inhibitor approved for the treatment of cutaneous T-cell lymphoma. and studies have demonstrated that it is able to induce HIV-1 gene expression in latently infected CD4 T cells from HIV-1 individuals on suppressive antiretroviral therapy. However, experiments suggested that RMD could also impair T-cell functionality, particularly of activated T cells. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3389/fimmu.2020.00418DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7100631PMC

-induced follicular mucinosis of the head and neck mimicking folliculotropic mycosis fungoides.

JAAD Case Rep 2020 Apr 24;6(4):266-272. Epub 2020 Mar 24.

Columbia University Irving Medical Center, Department of Dermatology, New York, New York.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.jdcr.2020.01.014DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7109359PMC

Sensitivity and specificity of T-cell receptor PCR BIOMED-2 clonality analysis for the diagnosis of cutaneous T-cell lymphoma.

Eur J Dermatol 2020 Feb;30(1):12-15

Department of Dermatology, University Hospital Zurich, University of Zurich, Zurich, Switzerland, Department of Dermatology, Lausanne University Hospital (CHUV) and the Faculty of Biology and Medicine, University of Lausanne, Lausanne, Switzerland.

Background: Early and precise diagnosis of cutaneous T-cell lymphomas (CTCL) is challenging. Currently, polymerase chain reaction (PCR)-based clonality assessment of the T-cell receptor (TCR) is a helpful tool for this diagnosis.

Objectives: In this retrospective study, we aimed to assess the sensitivity and specificity of this method for the diagnosis of CTCL. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1684/ejd.2020.3698DOI Listing
February 2020

Pigmented purpuric dermatosis in children: a retrospective cohort with emphasis on treatment and outcomes.

J Eur Acad Dermatol Venereol 2020 Apr 1. Epub 2020 Apr 1.

Division of Dermatology, Ann & Robert H. Lurie Children's Hospital of Chicago, Northwestern University, Chicago, IL, USA.

Background: Data regarding the course and treatment of pigmented purpuric dermatoses (PPD) in the paediatric population are limited. Although treatments for pigmented purpura are not well established, vitamin C and rutoside have been reported to be an effective treatment option and are widely utilized.

Objective: To assess the clinical course and utility of vitamin C and rutoside in paediatric patients with PPD treated at Ann & Robert H. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/jdv.16397DOI Listing